Kevin Tang, a director and 10% owner of Boundless Bio, Inc. (NASDAQ:BOLD), filed a Form 4 on November 10, 2026, disclosing two open-market purchases of Boundless Bio common stock totaling 1,949 shares made on November 6 and November 10, 2026.

Key Highlights

  • First purchase: 1,700 shares of common stock acquired on November 6, 2026, at a weighted-average price of $2.40 per share, with individual transaction prices ranging from $2.39 to $2.40.
  • Second purchase: 249 shares acquired on November 10, 2026, all at $2.40 per share.
  • Resulting ownership: Following both transactions, the reporting persons indirectly beneficially own 3,035,567 shares of Boundless Bio common stock.
  • Indirect ownership structure: Shares are held across four entities: Tang Capital Partners, LP (691,177 shares), Tang Capital Partners International, LP (974,622 shares), Tang Capital Partners III, Inc. (691,170 shares), and Tang Capital Partners IV, Inc. (678,598 shares).
  • Relationship to issuer: Kevin Tang is identified as both a director and a 10% owner of Boundless Bio, Inc.
  • Transaction codes: Both transactions are coded "P" (open-market purchase) in the filing.

Tang Capital Entities Add Boundless Bio Shares Across Two Trading Days

According to the Form 4 filed with the SEC, Kevin Tang made two separate purchases of Boundless Bio, Inc. common stock in November 2026. The first transaction, dated November 6, 2026, involved the acquisition of 1,700 shares at a weighted-average price of $2.40, with individual prices ranging from $2.39 to $2.40. The second transaction, dated November 10, 2026, covered 249 shares, all purchased at $2.40. Both transactions are classified as open-market purchases under transaction code "P."

The filing reports that all shares are held indirectly. As explained in the filing's footnotes, Tang Capital Partners, LP holds 691,177 shares; Tang Capital Partners International, LP holds 974,622 shares; Tang Capital Partners III, Inc. holds 691,170 shares; and Tang Capital Partners IV, Inc. holds 678,598 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which serves as the general partner of Tang Capital Partners, LP and Tang Capital Partners International, LP. Kevin Tang is also the sole director and Chief Executive Officer of Tang Capital Partners III, Inc. and Tang Capital Partners IV, Inc., which are indirectly wholly owned by Tang Capital Partners, LP. The filing states that "Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV."

Following both reported transactions, the aggregate indirect beneficial ownership reported stands at 3,035,567 shares. The filing also notes that the reporting persons will provide details on shares purchased at each specific price within the stated range upon request by the issuer, any security holder, or the SEC staff.

What Was Disclosed

Kevin Tang, a director and 10% owner, disclosed two open-market purchases of Boundless Bio common stock on November 6 and November 10, 2026, totaling 1,949 shares at prices of $2.39 to $2.40, resulting in indirect beneficial ownership of 3,035,567 shares held across four Tang Capital entities.